INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Post-transplant lymphoproliferative disorder (PTLD) following allogeneic hematopoietic cell transplant (HCT) is an aggressive disease impacting a young population and carrying a significant mortality rate in a relatively short time from diagnosis SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover , M.D., the
View HTML
Toggle Summary Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public
View HTML
Toggle Summary Atara Biotherapeutics Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it has commenced an underwritten
View HTML
Toggle Summary Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress
– Initiated two Phase 3 clinical studies to evaluate tab-cel™ (tabelecleucel) in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab and opened six MATCH and eight ALLELE study sites for  enrollment in the U.S.
View HTML
Toggle Summary Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
Launches Search for Chief Financial Officer SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today
View HTML
Toggle Summary Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance of its
View HTML
Toggle Summary Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover , M.D., the
View HTML
Toggle Summary Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public
View HTML
Toggle Summary Atara Biotherapeutics Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it has commenced an underwritten
View HTML